GentiBio and BMS partner to develop inflammatory bowel disease therapies
BMS will make development and commercial milestone payments of up to $1.9bn to GentiBio.
deal
Latest in
deal
Gemini enters business combination deal with Disc Medicine
The proceeds will be utilised to advance the pipeline of Disc to clinical trials and provide runway into 2025.
Catalent to purchase Metrics Contract Services from Mayne Pharma
Metrics’ Greenville facility will be integrated into oral development and manufacturing network of Catalent.
Cerevance and Merck partner to detect new Alzheimer’s targets
Cerevance is entitled to receive development and commercial milestone payments of nearly $1.1bn.
Sartorius to acquire UK’s Albumedix for $501.5m
With the acquisition, Albumedix will become part of the Bioprocess Solutions Division of Sartorius.
Pfizer signs agreement to acquire biopharma firm GBT for $5.4bn
GBT takeover complements and boosts Pfizer’s expertise in rare haematology.
Amgen to acquire biopharma firm ChemoCentryx for $3.7bn
The board of directors of Amgen and ChemoCentryx has granted unanimous approval for the acquisition.
Gilead Sciences signs agreement to acquire MiroBio for $405m
Gilead will gain access to the discovery platform and complete line of the immune inhibitory receptor agonists of MiroBio.